Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
28.75
-0.64 (-2.18%)
At close: Aug 26, 2026, 4:00 PM EDT
28.79
+0.04 (0.14%)
Pre-market: Aug 27, 2026, 4:42 AM EDT
Immunome Market Cap
Immunome has a market cap or net worth of $3.27 billion as of August 27, 2026. Its market cap has increased by 278.16% in one year.
Market Cap
3.27B
Enterprise Value
2.75B
1-Year Change
278.16%
Ranking
Category
Stock Price
$28.75
ChartMarket Cap Chart
Since the IPO on October 2, 2020, Immunome's market cap has increased from $111.39M to $3.27B, an increase of 2,831.44%. That is a compound annual growth rate of 77.26%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 26, 2026 | 3.27B | 37.78% |
| Dec 31, 2025 | 2.37B | 257.53% |
| Dec 31, 2024 | 662.87M | 44.98% |
| Dec 29, 2023 | 457.21M | 1,605.70% |
| Dec 30, 2022 | 26.80M | -82.91% |
| Dec 31, 2021 | 156.82M | 53.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 2, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Structure Therapeutics | 3.49B |
| AbCellera Biologics | 3.44B |
| uniQure | 3.29B |
| NewAmsterdam Pharma Company | 3.21B |
| MBX Biosciences | 3.20B |
| Tarsus Pharmaceuticals | 3.20B |
| Celldex Therapeutics | 3.19B |
| Arcutis Biotherapeutics | 3.11B |